Reactive arthritis following COVID-19: cause for concern.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36809513.
- Also identified by DOI 10.1007/s00167-023-07332-z and PMC identifier 9942056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Low-quality evidence suggests that COVID-19 may trigger reactive arthritis one to four weeks after the infection. Post COVID-19 reactive arthritis resolves within a few days, and no additional treatment is required. Established diagnostic or classification criteria for reactive arthritis are missing, and a deeper understanding of the immune mechanism related to COVID-19 prompt us to further investigate the immunopathogenic mechanisms capable of promoting or contrasting the development of specific rheumatic diseases. Caution should be exerted when managing post-infectious COVID-19 patient with arthralgia.
Medical subject headings
- Arthritis, Reactive
- COVID-19
- Rheumatic Diseases